COVID-19 trials registries data warehouse

http://www.chictr.org.cn/showproj.aspx?proj=50057

Wei Xiao

99xw@sina.com

2020-02-24

Recruiting

RCT

Randomized

Parallel

Not reported

single-center

Treatment

1. Sign the written informed consent, 2. Aged 18-80 years old, 3. Meet the diagnostic criteria for novel coronavirus infection(trial version sixth), confirmed by combining with the epidemiological history, clinical manifestations and etiology examination, 4. Course of disease within 14 days after onset.

1. Patients who are participating in clinical trials of other drugs, 2. Pregnant or lactating women, 3. ALT / AST > 2-fold ULN, 4. Expected survival time < 1 week, 5. With serious liver disease, 6. Patients taking orally anti-tumor drugs or immunomodulatory drugs for a long time, 7. Patients who are participating in other clinical trials, 8. The researchers think that other reasons are not suitable for clinical trials.

2

Jingzhou First People's Hospital

18

80

China

No restriction on type of patients

0: No restriction on type of patients

60

Endotracheal intubation rate;mortality;Ratio of virus nucleic acid detection to negative;

| Declared number of arm (2.0) differs from found arms (3.0)

Phase 0

[{"arm_notes": "", "treatment_id": 1604, "treatment_name": "Lopinavir+ritonavir", "treatment_type": "Antivirals", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2188, "treatment_name": "Standard of care", "treatment_type": "Standard of care", "pharmacological_treatment": "Standard of care"}]